Reasonable price Cas 159519-65-0 - Enfuvirtide – JYMed
Reasonable price Cas 159519-65-0 - Enfuvirtide – JYMed Detail:
Keywords
- high purity Enfuvirtide
- most affordable price
- CAS# 159519-65-0
Quick Details
- ProName: Enfuvirtide
- CasNo:159519-65-0
- Molecular Formula: C204H301N51O64
- Appearance: white powder
- Application: Human immunodeficiency virus type 1 (H…
- DeliveryTime: prompt shipment
- PackAge: according to customer’s requirements
- Port: Shenzhen
- ProductionCapacity: 2 Kilogram/Month
- Purity: 98%
- Storage: 2~8℃
- Transportation: by air
- LimitNum: 1 Gram
Superiority
professional peptide manufacturer in china.
high quality with gmp grade
large scale with competitive price
our products include: generic bulk peptide apis, cosmetic peptide, custom peptides and veterinary peptides.
molecular formula：
c204h301n51o64
relative molecular mass：
4491.945 g/mol
cas-number：
159519-65-0 (net)
long-term storage：
-20 ± 5°c
sequence：
ac-tyr-thr-ser-leu-ile-his-ser-leu-ile-glu-glu-ser-gln-asn-gln-gln-glu-lys-asn-glu-gln-glu-leu-leu-glu-leu-asp-lys-trp-ala-ser-leu-trp-asn-trp-phe-nh2 acetate salt
fields of application：
human immunodeficiency virus type 1 (hiv-1) infection
enfuviritide is used in combination with other antiretroviral agents in therapy-experienced patients with evidence of hiv-1 replication despite ongoing antiretroviral therapy.
active substance：
enfuvirtide is a 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of hiv-1 envelope protein.enfuvitide belongs to the therapeutic class of fusion inhibitors and acts by binding to gp41 and impeding the conformational changes in gp41 necessary for fusion of the virus with the cell.
Details
Company Profile:
company name:Shenzhen JYMed Technology Co.,Ltd.
Year Established:2009
Capital: 89.5 Million RMB
Main product: Oxytocin Acetate,Vasopressin Acetate,Desmopressin Acetate,Terlipressin acetate, Caspofungin acetate, Micafungin sodium, Eptifibatide acetate, Bivalirudin TFA, Deslorelin Acetate,Glucagon Acetate,Histrelin Acetate,Liraglutide Acetate,Linaclotide Aceteate ,Degarelix Acetate,Buserelin Acetate,Cetrorelix Acetate,Goserelin
Acetate, Argireline Acetate, Metrixyl Acetate,Snap-8,…..
We strive for continuing innovations in new peptide synthesis technology and process optimization, and our technical team have over decade of experience in peptide synthesis.JYM has successfully submitted a lot
of ANDA peptide APIs and formulated products with CFDA and have over fourty patents approved.
Our peptide plant is located in Nanjing, Jiangsu province and it has set up a facility of 30,000 square meters in compliance with cGMP guideline. The manufacture facility has been audited and inspected by both domestic and international clients.
With its excellent quality, most competitive price and strong technical support, JYM not only has gained recognitions for its products from Research organizations and Pharmaceutical industries, but also become one of the most reliable suppliers of peptides in China,. JYM is dedicated to be one of the world’s leading peptide provider in the near future.
Product detail pictures:
Related Product Guide:
全球抗肿瘤药物市场概览【3】-姜广策的博客-要么第一要么唯一！-搜狐博客 | Trelstar(Triptorelin Pamoate)
Bachem | Synthetic Angiotensin Ii Gmp Provider From China
To create much more benefit for consumers is our company philosophy; customer growing is our working chase for Reasonable price Cas 159519-65-0 - Enfuvirtide – JYMed, The product will supply to all over the world, such as: Lithuania, Latvia, Russia, Our products are mainly exported to Southeast Asia, the Middle East, North America and Europe. Our quality is surely guaranteed. If you are interested in any of our products or would like to discuss a custom order, please feel free to contact us. We are looking forward to forming successful business relationships with new clients around the world in the near future.
By Mona from Ethiopia - 2015.10.31 10:02
Products and services are very good, our leader is very satisfied with this procurement, it is better than we expected,
By Grace from Slovenia - 2016.03.28 12:22
